Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest ACE inhibitors Stories

2009-01-16 13:47:33

The Heart and Stroke Foundation is warning some Canadians with high blood pressure that a drug combination may put them at risk. Guidelines from the Canadian Hypertension Education Program urge patients who have been prescribed a combination of ACE inhibitors and Angiotensin II Receptor Blockers to see their family physicians as soon as possible for a treatment change. These two popular categories of hypertension medication are each safe and effective treatments -- but not together, Dr....

2008-11-12 12:00:31

Novartis has presented new clinical data which showed that the first-in-class direct renin inhibitor Rasilez, known as Tekturna in the US, provides significantly greater blood pressure reductions in patients with high blood pressure aged 65 and over, compared to the angiotensin-converting enzyme inhibitor ramipril. Results from the Ageless study showed that Rasilez/Tekturna provides an additional reduction in systolic blood pressure of 2.3mmHg in patients aged 65 and over compared to the...

2008-09-01 12:00:04

Boehringer Ingelheim Pharmaceuticals has reported primary results from the Transcend trial, which showed that treatment with Micardis 80mg in patients receiving current standard of care resulted in an 8% reduction in the composite endpoint of cardiovascular death, myocardial infarction, stroke and hospitalization for congestive heart failure. This reduction was not statistically significant (p=0.216; HR 0.92) compared to patients receiving placebo in addition to current standard of care....

2008-08-31 12:00:14

RIDGEFIELD, Conn., Aug. 31 /PRNewswire/ -- The primary results of the TRANSCEND(TM)* trial demonstrated that treatment with MICARDIS(R) (telmisartan) 80mg in patients receiving current standard of care resulted in an 8% reduction in the composite endpoint of cardiovascular death, myocardial infarction, stroke and hospitalization for congestive heart failure. This reduction was not statistically significant (p=0.216; HR 0.92) compared to patients receiving placebo in addition to current...

2008-06-25 03:01:35

By Popov, A F Hinz, J; Liakopoulos, O J; Schmitto, J D; Seipelt, R; Quintel, M; Schoendube, F A Aim. The angiotensin I-converting enzyme insertion/deletion polymorphism (ACE-I/D), including three genotypes (II, ID, DD), with a known impact on midterm mortality and morbidity in patiente after coronary artery bypass graft surgery (CABG), was studied. Since this polymorphism has been linked with increased vascular response to phenylephrine during cardiopulmonary bypass (CFB), we investigated...

2008-06-24 02:30:29

Glenmark Generics, a subsidiary of Glenmark Pharmaceuticals, has received ANDA approval from the FDA for Trandolapril tablets USP 1mg, 2mg and 4mg and will immediately commence marketing and distribution of these products in the US market. Glenmark's Trandolapril is an angiotensin converting enzyme inhibitor used to treat high blood pressure and is the generic equivalent of Mavik tablets marketed by Abbott Laboratories. This recent approval coupled with the three abbreviated new drug...

ccc772496c21368fb265a45403b94ba11
2008-03-31 13:05:00

Telmisartan is as effective as ramipril in reducing cardiovascular deathA major Canadian-led global study has found that a new blood pressure medication is effective in reducing cardiovascular death, with fewer side effects than the current standard of care. The study found a new drug telmisartan is as effective as the popular drug ramipril in reducing cardiovascular death in high risk patients and it has fewer side effects.Dr. Salim Yusuf, director of the Population Health Research Institute...

2008-03-31 12:00:11

CHICAGO, March 31 /PRNewswire/ -- Interim results from the ACCOMPLISH (Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension) trial demonstrate that high-risk, high blood pressure patients treated with Lotrel(R) (amlodipine besylate and benazepril HCl) had 20% fewer cardiovascular events than those taking a benazepril and hydrochlorothiazide (HCTZ) combination. This is the first cardiovascular outcomes trial in a hypertensive population...

2007-08-02 06:16:50

By Meredith, Peter A Key words: Candesartan - Cardiovascular disease - Heart failure - Hypertension ABSTRACT Therapeutic interventions that block the renin-angiotensin- aldosterone system (RAAS) have an important role in slowing the progression of cardiovascular risk factors to established cardiovascular diseases. In recent years, angiotensin receptor blockers (ARBs) have emerged as effective and well-tolerated alternatives to an anglotensin-converting enzyme Inhibitor (ACEi) for RAAS...

2007-06-10 06:00:11

By Telejko, Elwira Key words: Acceptability - L-Arginine - Bioequivalence - Perindopril - Shelf life - Stability ABSTRACT Background: The efficacy of the angiotensin-converting enzyme (ACE) inhibitor perindopril in the treatment of hypertension, stable coronary artery disease, and heart failure is well established. The reduced stability of the current salt, perindopril-tert-butylamine, in extreme climatic conditions has prompted research into more stable compounds. This article presents...